Helicobacter pylori is the most common chronic bacterial infection worldwide. Because of the risk for chronic gastritis, peptic ulcer disease, and gastric malignancy, all patients with H. pylori should be treated. Unfortunately, eradication rates remain low, and barriers to successful treatment include inadequate acid suppression, locoregional antibiotic resistance, and patient nonadherence to complicated treatment regimens. Vonoprazan, a new medication for the treatment of H. pylori infections, provides more potent acid suppression and is simpler to dose than proton pump inhibitors. This activity provides a data-driven algorithm for incorporating vonoprazan into the treatment of patients with H. pylori infections.

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe the epidemiology and pathophysiology of H. pylori infection
• Discuss the barriers to successful eradication of H. pylori infection
• Describe vonoprazan’s mechanism of action, indications, contraindications, and adverse reactions
• Develop a data-driven approach to treatment of H. pylori infection

---

Minimally Invasive Treatments for Chronic Low Back Pain

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe the common pathophysiologies of LBP
• Describe the initial approach to diagnosing and managing LBP
• List the circumstances in which a patient with LBP should be promptly referred to a specialist
• List recent updates in the treatment of LBP from the specialist and primary care perspectives